NO20033300L - 1-aryl- eller 1-arylsulfonylbenzazolderivater som 5- hydroksytryptamin-6 ligander - Google Patents

1-aryl- eller 1-arylsulfonylbenzazolderivater som 5- hydroksytryptamin-6 ligander

Info

Publication number
NO20033300L
NO20033300L NO20033300A NO20033300A NO20033300L NO 20033300 L NO20033300 L NO 20033300L NO 20033300 A NO20033300 A NO 20033300A NO 20033300 A NO20033300 A NO 20033300A NO 20033300 L NO20033300 L NO 20033300L
Authority
NO
Norway
Prior art keywords
arylsulfonylbenzazole
hydroxytryptamine
ligands
aryl
derivatives
Prior art date
Application number
NO20033300A
Other languages
English (en)
Norwegian (no)
Other versions
NO20033300D0 (no
Inventor
Michael Gerard Kelly
Ping Zhou
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20033300D0 publication Critical patent/NO20033300D0/no
Publication of NO20033300L publication Critical patent/NO20033300L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
NO20033300A 2001-01-23 2003-07-22 1-aryl- eller 1-arylsulfonylbenzazolderivater som 5- hydroksytryptamin-6 ligander NO20033300L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26342501P 2001-01-23 2001-01-23
PCT/US2002/001950 WO2002059088A1 (en) 2001-01-23 2002-01-18 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands

Publications (2)

Publication Number Publication Date
NO20033300D0 NO20033300D0 (no) 2003-07-22
NO20033300L true NO20033300L (no) 2003-09-03

Family

ID=23001722

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033300A NO20033300L (no) 2001-01-23 2003-07-22 1-aryl- eller 1-arylsulfonylbenzazolderivater som 5- hydroksytryptamin-6 ligander

Country Status (23)

Country Link
US (4) US6509357B1 (de)
EP (1) EP1353904B9 (de)
JP (1) JP4208573B2 (de)
KR (1) KR20030068591A (de)
CN (1) CN1273450C (de)
AR (1) AR034203A1 (de)
AT (1) ATE312078T1 (de)
AU (1) AU2002251811B2 (de)
BR (1) BR0206633A (de)
CA (1) CA2435566A1 (de)
DE (1) DE60207815T2 (de)
DK (1) DK1353904T3 (de)
EA (1) EA006057B1 (de)
ES (1) ES2250638T3 (de)
HU (1) HUP0401009A3 (de)
IL (1) IL157059A0 (de)
MX (1) MXPA03006479A (de)
NO (1) NO20033300L (de)
NZ (1) NZ527051A (de)
PL (1) PL364568A1 (de)
TW (1) TW593278B (de)
WO (1) WO2002059088A1 (de)
ZA (1) ZA200306542B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL158448A0 (en) * 2001-04-20 2004-05-12 Wyeth Corp Heterocyclylalkoxy- alkylthio-and-alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
EA200301142A1 (ru) * 2001-04-20 2004-02-26 Уайт Производные гетероциклилокси-, -тиокси- и -аминобензазола в качестве лигандов 5-гидрокситриптамина-6
PL367305A1 (en) * 2001-06-07 2005-02-21 F.Hoffmann-La Roche Ag New indole derivatives with 5-ht6 receptor affinity
AU2003209114A1 (en) * 2002-02-14 2003-09-04 Wyeth Pyrrolylalkylidene-hydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands
AU2003237705B2 (en) * 2002-06-05 2009-07-30 F. Hoffmann-La Roche Ag 1-sulfonyl-4-aminoalkoxy indole derivatives as 5-HT6-receptor modulators for the treatment of CNS-disorders
AU2003268117A1 (en) * 2002-09-18 2004-04-08 Eli Lilly And Company Histamine h3 receptor antagonists, preparaton and therapeutic uses
TWI284124B (en) * 2002-12-03 2007-07-21 Hoffmann La Roche Aminoalkoxyindoles
PL378120A1 (pl) * 2003-02-14 2006-03-06 Wyeth Heterocyklilo-3-sulfonyloindazole jako ligandy 5-hydroksytryptaminy
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
SE0302760D0 (sv) * 2003-10-20 2003-10-20 Biovitrum Ab New compounds
JP2007523938A (ja) 2004-02-27 2007-08-23 エフ．ホフマン−ラ　ロシュ　アーゲー ピラゾールの縮合誘導体
CN1922150A (zh) 2004-02-27 2007-02-28 霍夫曼-拉罗奇有限公司 吲唑衍生物以及含有它们的药物组合物
KR100844864B1 (ko) 2004-02-27 2008-07-09 에프. 호프만-라 로슈 아게 헤테로아릴-융합 피라졸로 유도체
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
CA2815550C (en) * 2004-10-08 2015-12-29 I-Con Systems, Inc. Diaphragm valve with electronic pressure detection
EP1809607B1 (de) 2004-11-02 2008-12-17 Pfizer, Inc. Sulfonylbenzimidazolderivate
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US7582636B2 (en) 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
CA2619010C (en) * 2005-08-15 2013-10-01 Wyeth Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands
KR101011956B1 (ko) 2005-08-25 2011-01-31 에프. 호프만-라 로슈 아게 Ｐ３８ ｍαｐ 키나아제 저해제 및 이의 사용 방법
TW200804345A (en) * 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
AU2007210073B2 (en) 2006-01-31 2011-10-06 Array Biopharma Inc. Kinase inhibitors and methods of use thereof
KR20090006148A (ko) * 2006-04-05 2009-01-14 와이어쓰 5-히드록시트립타민-6 리간드로서의 설포닐-3-헤테로시클릴인다졸 유도체
WO2007120596A1 (en) * 2006-04-12 2007-10-25 Wyeth DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
BRPI0712730A2 (pt) * 2006-06-01 2013-12-17 Wyeth Corp Composto da fórmula i; método para o tratamento de um distúrbio do sistema nervoso central relacionado ou afetado pelo receptor 5-ht6 em um paciente que dele necessita; composição farmacêutica; processo para a preparação de um composto da fórmula ia; e uso de um composto da fórmula i
US20090023925A1 (en) * 2007-06-28 2009-01-22 Wyeth N'-(2-halobenzylidene)sulfonylhydrazides as intermediates in the manufacture of arylsulfonylindazoles
ES2616238T3 (es) 2010-10-06 2017-06-12 Glaxosmithkline Llc, Corporation Service Company Derivados de bencimidazol como inhibidores de PI3 quinasa
WO2015090233A1 (en) 2013-12-20 2015-06-25 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic compounds and their application in pharmaceuticals
EP3166924B1 (de) 2014-07-08 2019-02-20 Sunshine Lake Pharma Co., Ltd. Aromatische heterocyclische derivate und pharmazeutische anwendungen davon
EP4105203A1 (de) 2016-09-30 2022-12-21 Epizyme Inc Spiro-kondensierten indol-verbindungen als ehmt2-inhibitoren
WO2018195450A1 (en) 2017-04-21 2018-10-25 Epizyme, Inc. Combination therapies with ehmt2 inhibitors
RU2020118594A (ru) 2017-11-06 2021-12-09 Рапт Терапьютикс, Инк. Противораковые агенты
CN112847099A (zh) * 2021-03-08 2021-05-28 王佳丽 一种有效调节进给量实现自动切割的砂轮切割机

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2905877A1 (de) * 1979-02-16 1980-08-28 Boehringer Mannheim Gmbh Neue aminopropanolderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
JPH09506885A (ja) * 1993-12-21 1997-07-08 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ▲下１ｄ▼（抗うつ作用）活性を有するインドール、インドリンおよびキノリン誘導体
GB9416972D0 (en) 1994-08-23 1994-10-12 Smithkline Beecham Plc Carbon side chain/indole/indolene
EP0871442A1 (de) * 1996-01-09 1998-10-21 Eli Lilly And Company Benzimidzolyl neuropeptidy rezeptor antagonisten
GB9600344D0 (en) 1996-01-09 1996-03-13 Lilly Co Eli Benzimidzolyl neuropeptide y receptor antagonists
AU2139097A (en) * 1996-03-01 1997-09-16 Eli Lilly And Company Methods of treating or preventing sleep apnea
WO1998030548A1 (en) 1997-01-13 1998-07-16 Yamanouchi Pharmaceutical Co., Ltd. 5-HT2c RECEPTOR AGONISTS AND AMINOALKYLINDAZOLE DERIVATIVES
US5872144A (en) 1997-02-18 1999-02-16 American Home Products Corporation 4-aminoethoxyindazole derivatives
US6127380A (en) 1997-02-18 2000-10-03 American Home Products Corporation 4-aminoalkoxy-1H-benzoimidazoles
ATE295369T1 (de) 1998-03-31 2005-05-15 Bristol Myers Squibb Pharma Co Pharmazeutika zur bildgebung der angiogenischen krankheiten
GB9820113D0 (en) * 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
DE69936148T2 (de) * 1998-12-18 2008-01-24 Bristol-Myers Squibb Pharma Co. Vitronektinrezeptorantagonist-arzneimittel
GB9902452D0 (en) * 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB0019950D0 (en) * 2000-08-12 2000-09-27 Smithkline Beecham Plc Compounds

Also Published As

Publication number Publication date
NZ527051A (en) 2005-07-29
US20040087637A1 (en) 2004-05-06
AU2002251811B2 (en) 2007-06-21
TW593278B (en) 2004-06-21
DK1353904T3 (da) 2006-02-20
EP1353904B9 (de) 2006-05-03
AR034203A1 (es) 2004-02-04
EA006057B1 (ru) 2005-08-25
PL364568A1 (en) 2004-12-13
US20030149018A1 (en) 2003-08-07
DE60207815T2 (de) 2006-08-24
US20040092564A1 (en) 2004-05-13
DE60207815D1 (de) 2006-01-12
WO2002059088A1 (en) 2002-08-01
HUP0401009A3 (en) 2004-10-28
ATE312078T1 (de) 2005-12-15
MXPA03006479A (es) 2003-09-22
EP1353904A1 (de) 2003-10-22
US6919354B2 (en) 2005-07-19
ES2250638T3 (es) 2006-04-16
ZA200306542B (en) 2005-11-21
EP1353904B1 (de) 2005-12-07
JP4208573B2 (ja) 2009-01-14
CN1498209A (zh) 2004-05-19
BR0206633A (pt) 2004-02-17
JP2004521116A (ja) 2004-07-15
IL157059A0 (en) 2004-02-08
NO20033300D0 (no) 2003-07-22
HUP0401009A2 (hu) 2004-08-30
CA2435566A1 (en) 2002-08-01
EA200300829A1 (ru) 2003-12-25
US6509357B1 (en) 2003-01-21
CN1273450C (zh) 2006-09-06
KR20030068591A (ko) 2003-08-21
US6710069B2 (en) 2004-03-23

Similar Documents

Publication Publication Date Title
DK1353904T3 (da) 1-Aryl- eller 1-alkylsulfonylbenzazolderivater som 5-hydroxytryptamin-6-ligander
NO20031977L (no) 1-aryl- eller 1-alkylsulfonyl-heterocyklylbenzazoler som 5- hydroksytryptamin-6-ligander
DK1456206T3 (da) Azaindolylalkylaminderivater som 5-hydroxytryptamin-6-ligander
DK1455779T3 (da) Indolylalkylaminderivater som 5-hydroxytryptamin-6-ligander
DK1355904T3 (da) Heterocyclindazol- og -azaindazolforbindelser som 5-hydroxytryptamin-6-ligander
DK1509522T3 (da) 1-(Aminoalkyl)-3-sulfonylazaindoler som 5-hydroxytryptamin-6-ligander
DK1414803T3 (da) Pyrazolylcarboxanilider som fungicider
NO20034648L (no) Hydroksycyklyloksy-, tioksy- og -aminobenzazol-derivater som 5-hydroksytryptamin-6-ligander
NO20035775L (no) 3-fluor-pyrrolidiner som anti-diabetesmidler
IL166138A0 (en) 1-heterocyclylalkyl-3-sulfonylindole or indazole derivatives as 5-hydroxytryptamine-6 ligands
IL166139A0 (en) 1-heterocycylalkyl-3-sulfonylazaindole or- azaindazole derivatives as 5-hydroxytryptamine-6 ligands
NO20032531D0 (no) Tetralon-derivater som antitumormidler
DK1355900T3 (da) Heterocyclylalkylindol- eller -azaindolforbindelser som 5-hydroxytryptamin-6-ligander
DK1509501T3 (da) 1-(Aminoalkyl)-3-sulfonylindol- og indazolderivater som 5-hydroxytryptamin-6-ligander
DE50209511D1 (de) Kreiselpumpe
DK1429607T3 (da) Delta-1-pyrroliner som pesticider
NO20034647D0 (no) Hydroksyclylalkoksy-, alkyloksy- og -alkylaminobenzazol- derivater som 5-hydroksytryptamin-6-ligander
DK1322654T3 (da) Platinkomplekser som antitumormidler
NO20014597D0 (no) Fremgangsmåte
NO20033234L (no) Karotenoider som antihypertensjonsmidler
HK1056561A (en) 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
HK1066002A (en) Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
HK1060128A (en) Heterocyclyloxy-, -thioxy-and-aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
HK1060880A (en) Heterocyclylalkoxy-, -alkylthio- and - alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application